The combination with easing COVID restrictions and the access to funds via Flerie Invest AB is a good combination that gives Nanologica an extended window of opportunity to establish sales and a commercial pipeline of interest in preparative chromatography. However, this is also a necessity that the low sales activity in Q4 confirms.